Takeda Pharmaceutical (NYSE:TAK) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a buy rating in a research note released on Saturday.

TAK has been the topic of several other research reports. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Finally, Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $17.15 on Friday. The stock’s fifty day moving average is $16.12 and its two-hundred day moving average is $16.97. The company has a market capitalization of $54.59 billion, a PE ratio of 43.98 and a beta of -0.07. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. As a group, analysts expect that Takeda Pharmaceutical will post 1.12 earnings per share for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership raised its holdings in shares of Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after acquiring an additional 2,854,069 shares in the last quarter. UBS Group AG lifted its stake in Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd grew its holdings in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after acquiring an additional 1,426,184 shares in the last quarter. Van ECK Associates Corp grew its holdings in Takeda Pharmaceutical by 98.4% during the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after acquiring an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its position in Takeda Pharmaceutical by 1,070.7% during the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after purchasing an additional 880,289 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.